Power Point Presentation - Research Methodologies in Real World Drug Safety and Comparative Effectiveness

[ PDF (49 KB) | Help ]

[Slide 1]

Research Methodologies in Real World Drug Safety and Comparative Effectiveness

November 19, 2010

Ian Graham, PhD
Vice-President,
Knowledge Translation and Public Outreach
Canadian Institutes of Health Research

[Slide 2]

Canadian Institutes of Health Research (CIHR)

• CIHR:
  • is the Government of Canada's health research funding agency with a mandate "to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system”
  • designed to respond to evolving needs and seeks to transform health research in Canada

[Slide 3]

Knowledge Translation and DSEN

• DSEN objectives:
  • To increase the available evidence on drug safety and effectiveness available to regulators, policy makers, health care providers and patients,
  • Increase capacity within Canada to undertake high quality post-market studies of real world safety and effectiveness to support increased availability of needed evidence
• DSEN’s approaches:
  • A partnership between CIHR and Health Canada in collaboration with other stakeholders
  • Takes an integrated knowledge translation (iKT) approach to drug safety and effectiveness research

[Slide 4]

What is iKT?

• A way of doing research where the researcher engages potential knowledge users as partners in the research process
• Collaborative, participatory, action-oriented, community-based research, co-production of knowledge, mode 2 knowledge production
• Involves engaging and integrating knowledge users into the research process
• Knowledge users can be:
  • Policy- and decision-makers from the community to the federal level, researchers, industry, clinicians, the public, and patients
  • Investigators from different disciplines, teams, countries